Calysta and Nofima have announced they will partner to conduct large-scale trials in Atlantic salmon using Calysta’s FeedKind®protein as a means to improve feed efficiency and fish health.
FeedKind has been shown to improve key nutritional metrics for commercial aquaculture – increased feed efficiency and the maintenance of a healthy digestive tract and immune system. It provides the industry with the first scalable alternative protein requiring no wild caught fish or agricultural land, contributing to global food security. The trials, to be designed by Nofima, will begin in early 2019.
Mari Moren, director of research at Nofima, said: “We are eager to do research on FeedKind as we believe that this may be an example of new protein sources that can contribute to a more sustainable aquaculture. Feedkind’s effect on salmon will be thoroughly tested at Nofima’s research facilities along with the effects this protein may have on the physicochemical qualities of the feed pellet.”